NEW YORK--(BUSINESS WIRE)--March 9, 2006--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has announced that Dr. Arthur Sytkowski, Associate Professor of Medicine at Harvard University, has agreed to serve as Callisto’s Clinical Trial Advisor and Medical Safety Monitor. Dr. Sytkowski will advise on Callisto’s expanding clinical programs to develop its anticancer drugs Atiprimod and L-Annamycin.
